Evidence map›Paper›PMID 37308721›Full record

ArticleNature metabolism2023

Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice.

Jonathan M Weiss, Erika M Palmieri, Marieli Gonzalez-Cotto, Ian A Bettencourt, Emily L Megill, Nathaniel W Snyder, Daniel W McVicar

Open access · hybridAbstract read
In one paragraph

Article in Nature metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Itaconate and its derivatives in human health and diseases.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Role of itaconate in intestinal disease (Review).International journal of molecular medicine · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jonathan M Weiss *Cancer Innovation Laboratory, Center for Cancer Research, NCI Frederick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-4467-5611
Erika M Palmieri *Cancer Innovation Laboratory, Center for Cancer Research, NCI Frederick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-4237-5324
Marieli Gonzalez-CottoCancer Innovation Laboratory, Center for Cancer Research, NCI Frederick, Frederick, MD, USA.
Ian A BettencourtCancer Innovation Laboratory, Center for Cancer Research, NCI Frederick, Frederick, MD, USA.ORCID http://orcid.org/0000-0001-8154-7670
Emily L MegillDepartment of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Nathaniel W SnyderDepartment of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-5643-8747
Daniel W McVicarCancer Innovation Laboratory, Center for Cancer Research, NCI Frederick, Frederick, MD, USA. mcvicard@mail.nih.gov.ORCID http://orcid.org/0000-0002-1112-5111
Center for Cancer Research · USTemple University · USFrederick National Laboratory for Cancer Research · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Signal Transduction of Paired Inhibitory Receptors of NK Cells and MacrophagesZIABC010300 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCVICAR, DANIEL W. · 2009 to 2025
$24.6M
Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Gavin E Arteel · 2019 to 2026
$10.9M
Quantification of compartmentalized metabolism in eukaryotic systemsR01GM132261 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI SNYDER, NATHANIEL W. · 2019 to 2023
$1.8M
NIDDK NIH HHS P30 DK120531NIEHS NIH HHS P30 ES013508NIGMS NIH HHS R01 GM132261
6 · The paper itself

Abstract

Itaconate, the product of the decarboxylation of cis-aconitate, regulates numerous biological processes. We and others have revealed itaconate as a regulator of fatty acid β-oxidation, generation of mitochondrial reactive oxygen species and the metabolic interplay between resident macrophages and tumors. In the present study, we show that itaconic acid is upregulated in human non-alcoholic steatohepatitis and a mouse model of non-alcoholic fatty liver disease. Male mice deficient in the gene responsible for itaconate production (immunoresponsive gene (Irg)-1) have exacerbated lipid accumulation in the liver, glucose and insulin intolerance and mesenteric fat deposition. Treatment of mice with the itaconate derivative, 4-octyl itaconate, reverses dyslipidemia associated with high-fat diet feeding. Mechanistically, itaconate treatment of primary hepatocytes reduces lipid accumulation and increases their oxidative phosphorylation in a manner dependent upon fatty acid oxidation. We propose a model whereby macrophage-derived itaconate acts in trans upon hepatocytes to modulate the liver's ability to metabolize fatty acids.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsFatty AcidsHepatocytesHumansLipid MetabolismLipidsMaleMiceSuccinatesFatty Acidsitaconic acidLipidsSuccinates

Identifiers

PMID37308721
PMCPMC10290955
OpenAlexW4380360243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.